Tela Bio, Inc., founded in the United States, is a biotechnology company dedicated to developing advanced surgical solutions for soft tissue repair and reconstruction. Their core mission is to optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. Tela Bio offers a growing portfolio of innovative products designed to leverage the body's natural healing response while minimizing long-term exposure to permanent synthetic materials. Their market focus is primarily on healthcare providers and patients requiring surgical soft tissue repair.

Notable affiliated individuals include key figures in the biotech and medical fields, contributing to Tela Bio's robust research and development efforts. The company has attracted significant investment from prominent venture capital firms specializing in healthcare innovation. Tela Bio's key achievements include the successful development and commercialization of several groundbreaking products that have improved patient outcomes in soft tissue reconstruction. Their impact is evident in the enhanced quality of life for patients and the advancement of surgical techniques in the medical community.